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Abstract
Background: The present study was undertaken to find out the role of estrogen pathway related gene polymorphisms in
susceptibility to migraine in Northern Indian population. Aromatase, CYP19A1 (rs10046 and rs4646); estrogen receptors,
ESR1 (rs2234693, rs1801132, rs2228480 and rs9340799) and ESR2 (rs1271572 and rs1256049) polymorphisms were selected
for the present study.
Methodology/Principal Findings: The patients were recruited in two cohorts – primary (207) and replicative (127) along
with 200 healthy controls and genotyped for various polymorphisms. Logistic regression analysis was applied for statistical
analyses. The results were validated in the replicative cohort and pooled by meta analysis using Fisher’s and Mantel-
Haenszel test. Furthermore, Benjamini – Hochberg false discovery rate test was used to correct for multiple comparisons.
CYP19A1 rs10046 and CYP19A1 rs4646 polymorphisms were found to confer risk and protective effect, respectively. Out of
four ESR1 polymorphisms, only rs2234693 variant allele was significantly associated in migraine with aura. No significant
associations were observed for ESR2 polymorphisms. Significant haplotypes were identified for CYP19A1 and ESR1
polymorphisms. Gene- gene interactions of genotypes as well as haplotypes were observed for CYP19A1- ESR1 showing
both risk and protective combinations.
Conclusion: We strongly suggest CYP19A1 polymorphisms to be the major contributing factors in migraine susceptibility
instead of genetic variants of estrogen receptors.
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Introduction
Migraine is a debilitating neurological disorder affecting about
10% of world’s population [1]. It can be broadly classified into two
types- Migraine without aura (MO) and Migraine with aura (MA).
It is a complex disorder involving interplay between genes and
environmental factors. The exact pathophysiology of migraine is
still unclear. However, the gender biasness in the incidence of
migraine has paved the way for hormonal theory. Fluctuating
hormone (especially estrogen) levels in women are considered to be
the major contributing factors. It is observed that both estrogen
withdrawal as well as high estrogen levels increase migraine risk in
women [2]. Various genes of estrogen pathway are involved in
estrogen signaling and its downstream effects. Hence, a detailed
understanding of the polymorphisms and their functional effects
may provide useful insights in the field of migraine pathophysi-
ology.
CYP19A1 (cytochrome P450, family 19, subfamily A, polypep-
tide 1) gene encodes aromatase enzyme which is involved in the
final step of estrogen synthesis. Varying estrogen levels are
associated with polymorphisms in the 39 UTR (rs10046 C.T
and rs4646 G.T) of this gene [3,4]. However, there is a single
study on role of rs10046 polymorphism in migraine [5].
Estrogen imparts its genomic effects through its receptors. The
most common are the ligand gated receptors (ESRa encoded by
ESR1 gene and ESRb encoded by ESR2 gene). Many studies in
migraine have focused on ESR1 gene polymorphisms. Intronic
polymorphisms [rs2234693 (ESR1 PvuIIC.T) and rs9340799
(ESR1 XbaIA.G)] are associated with serum estradiol concentra-
tions [6,7]. The rs2234693 has been previously studied [8]
whereas the other intronic polymorphism (rs9340799) has not yet
been explored in migraine. Reports on synonymous exonic
polymorphisms [rs1801132 (C325G) and rs2228480 (G594A)] of
ESR1with migraine are conflicting [8,9,10,11,12]. Two of the
above polymorphisms (rs2234693 and rs1801132) have also been
studied by our group previously [13]. ESR2 promoter polymor-
phism (rs1271572) may influence transcriptional factor binding
and gene expression [14]. On the other hand, exonic polymor-
phism (rs1256049) results in a silent change which may affect
mRNA folding, transcription and stability [15]. These polymor-
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like cardiovascular disorder [15]. However, no group has studied
these polymorphisms in migraine.
The present study was undertaken to explore the role of
polymorphisms in genes of estrogen pathway in migraine
susceptibility in Northern Indian population. The CYP19A1
(rs10046 and rs4646), ESR1 (rs2234693, rs1801132, rs2228480
and rs9340799) and ESR2 (rs1271572 and rs1256049) polymor-
phisms were selected for the present study. The conflicting reports
on ESR1 gene polymorphisms and lack of reports on CYP19A1 and
ESR2 gene polymorphisms led us to validate the results in a
replicative cohort and finally pooling the results by meta analysis.
Results
The genotypic and allelic frequencies of the study subjects are
shown in Tables S1, S2, S3, S4, S5, S6, S7, and S8. All the studied
polymorphisms followed Hardy Wienberg equilibrium in the
control population.
CYP19A1 gene polymorphisms (rs10046 and rs4646)
CYP19A1 rs10046 polymorphism. In the primary cohort,
the frequencies of heterozygous (CT) and variant (TT) genotypes
were significantly higher (p,0.001) in migraine patients as
compared to healthy controls (HC). In case of CT, subgroup
analysis showed significant association in migraine without aura
(MO) only. Further subgroup analysis on the basis of gender also
yielded statistically significant results in migraine and MO for both
the genders. However, the results could be replicated in females
only. Significant associations were observed for TT genotype in
both migraines without and with aura (MA). Sub stratification on
the basis of gender yielded significant results in females only. All
the significant results were replicated. Similarly, we found
statistically significant p values (pcorr=0.01) on applying Fisher’s
method. Mantel – Haenszel test odds ratios confirmed the risk of
heterozygous and variant genotypes in migraine susceptibility
(Table 1).
At allelic level, significant results were seen with migraine as well
as subgroups in the primary cohort except male MA (data not
shown). All the results were replicated except for males. On
pooling the data, significance was retained in all these subgroups
(pcorr=0.01) showing risk of variant allele. Carrier analysis using
dominant model showed highly significant results with migraine
and its subgroups. However significance could not be obtained in
male patients (Table 1).
CYP19A1 rs4646 polymorphism. In the primary cohort, the
heterozygous (GT) genotype did not show significant associations
with migraine or its clinical subgroups (data not shown). However,
on gender stratification, female migraine patients (p=0.022;
OR=0.544) and female MA patients (p=0.015; OR=0.427)
showed protective effect. We were able to replicate the results. On
pooling, significant results were obtained in both the subgroups
showing an overall protective effect of the genotype (Table 2).
At allelic level, protective effect of the variant T allele was
evident in MA patients in both the cohorts. Similar associations
were observed for female migraine and female MA patients.
Furthermore, we found highly significant associations on pooling.
In addition, dominant model also showed significant results for
female migraine patients and female MA patients in both the
cohorts as well as on pooling (Table 2).
CYP19A1: LD and Haplotype Analysis. On LD analysis, D9
value of 0.4637 was observed, suggesting a moderate linkage
disequilibrium. The frequency of rs10046T-rs4646G haplotype
was significantly higher in patients of both primary (37.7%) and
replicative (33.1%) cohorts as compared to HC (20.0%), imparting
significant results. Similar results were obtained for the rs10046T-
rs4646T haplotype. The pooling of data validated these results
(Table 3). On subgrouping, similar results were observed for MO.
However, we did not find significant predominance of any
haplotype groups in MA. Furthermore, stratification on the basis
of gender again yielded significant results for rs10046T-rs4646G
haplotype. No significant associations were observed for other
haplotype groups. All the significant observations were replicated
and validated (Table 3).We did not find any association in male
subgroups (data not shown).
ESR1 gene polymorphisms (rs2234693, rs1801132,
rs2228480 and rs9340799)
Four polymorphisms of ESR1 gene were explored for associa-
tion with migraine and its clinical subgroups. In rs2234693, the
variant allele (T) showed a borderline significance in MA patients
in the primary cohort. Significant differences were observed in the
replicative cohort. The risk of the variant allele was evident on
data pooling (Table 4). No significant differences in genotypic and
allelic distribution of rs1801132, rs2228480 and rs9340799
polymorphisms were observed among migraine patients and HC
in both the cohorts. On sub-classification of migraine patients into
MO and MA, the genotypic and allelic distributions were found to
be insignificant when compared to HC. Further stratification of
data on gender basis also did not yield any significant results
(Table 4).
ESR1: LD and Haplotype Analysis. ESR1 rs2234693 and
rs9340799 were in strong linkage disequilibrium (D9=0.6222). No
other pairs of polymorphisms were found to be in linkage
disequilibrium (D9,0.5). Haplotypes were constructed for the
selected polymorphisms (Table S9). The haplotype comprising of
the entire wild ones (A) was taken as reference. In the primary
cohort, frequency of one of the haplotype group (B) was found to
be significantly lower in patients as compared to controls. The
result was replicated and pooling also confirmed the association
(pcorr=0.01) showing a protective effect (OR=0.129) (Table S9).
ESR2 gene polymorphisms (rs1271572 and rs1256049)
No significant associations were observed for rs1271572 and
rs1256049 at genotypic and allelic levels. No significant differences
were evident on subgroup analysis (Table S10). Furthermore, these
two polymorphisms were not in linkage disequilibrium
(D9=0.3649).
Gene- gene interactions
The CYP19A1 rs10046 polymorphism was found to have
significant interactions with both ESR1 and ESR2 gene polymor-
phisms. Significant interactions were observed for CYP19A1
rs10046 with ESR2 rs1271572, ESR1 rs2234693 and ESR1
rs9340799 polymorphisms conferring risk for migraine suscepti-
bility. Combinations of ESR2 rs1271572 AC genotype with both
heterozygous as well as variant genotypes of CYP19A1 rs10046
were significantly higher in patients as compared to controls.
These interactions were replicated and validated on pooled
analysis (Table 5). However, the degree of association was not
increased on interaction than the one observed in case of
individual (rs10046) polymorphism.
The SNPs of CYP19A1-ESR1 also interacted significantly.
Combinations with two of the ESR1 polymorphisms (rs2234693
and rs9340799) and CYP19A1 rs10046 were significantly higher in
patients. In these polymorphisms, each of the heterozygous –
variant genotype combination was found to be significantly
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validated showing significantly higher risk for patients having these
genotype combinations. Furthermore, the risk was increased in all
these interactions than observed for individual polymorphisms
(Table 5).
TheCYP19A1rs4646polymorphismwasfoundto have significant
interactions with only ESR1 rs9340799 polymorphism. The
combination of heterozygous genotypes of these polymorphisms
conferred a significant (pcorr=0.01) protective effect (ORMH=
0.3457) (Table 5). No significant associations were observed with
other ESR1 or ESR2 polymorphisms (data not shown).
Gene- gene interactions of haplotypes
The CYP19A1 and ESR1 haplotypes were analyzed for
interactions. Interactions between a single haplotype combination
(CYP19A1 01-ESR1 H) was significantly associated and another
(CYP19A1 10-ESR1 H) combination and showed borderline
association in the primary cohort. However, only one of the
interactions (CYP19A1 01-ESR1 H) was replicated. Furthermore,
on pooling both these interactions (CYP19A1 01-ESR1 H and
CYP19A1 10-ESR1 H) were found to have significant protective
effect and risk respectively (Table 6).
Discussion
Migraine is predominant in women as compared to men (3:1)
[16]. The role of female hormones especially estrogen cannot be
overlooked in this gender biasness. Hence, studies have focused on
the relationship between estrogen and migraine. However, studies
in genetic polymorphisms in estrogen pathway have been limited
Table 1. Association study of CYP19A1 rs10046 polymorphism.
Primary cohort Replicative cohort Meta analysis
Fisher’s method
Benjamini-
Hochberg FDR
test Mantel-Haenszel test
Association of CT genotype with migraine susceptibility
p
a OR(95%CI) p
a OR(95%CI) X
2 p
a pcorr
a ORMH(95%CI)
Migraine Vs HC ,0.0001 2.937(1.893–4.556) ,0.0001 2.817(1.708–4.645) 46.66 ,0.0001 0.01 1.925(1.431–2.59)
MO Vs HC ,0.0001 3.907(2.291–6.661) ,0.0001 3.103(1.785–5.397) 48.46 ,0.0001 0.01 2.159(1.548–3.012)
Females
Migraine Vs HC 0.001 2.560(1.507–4.349) 0.00018 3.165(1.732–5.784) 31.06 ,0.0001 0.01 1.724(1.207–2.464)
MO Vs HC 0.00027 3.287(1.730–6.243) ,0.0001 3.385(1.740–6.587) 32.48 ,0.0001 0.01 1.974(1.321–2.951)
Association of TT genotype with migraine susceptibility
Migraine Vs HC ,0.0001 9.958(4.328–22.913) ,0.0001 6.687(2.637–16.961) 52.64 ,0.0001 0.01 4.641(2.589–8.32)
MO Vs HC ,0.0001 13.134(5.301–32.542) 0.0001 3.103(1.785–5.397) 53.88 ,0.0001 0.01 4.749(2.576–8.756)
MA Vs HC 0.00018 6.579(2.446–17.692) 0.013 6.052(1.467–24.970) 25.92 ,0.0001 0.01 4.552(2.151–9.632)
Females
Migraine Vs HC ,0.0001 14.681(4.806–44.846) 0.00018 10.314(3.043–34.952) 43.14 ,0.0001 0.01 7.095(3.243–15.53)
MO Vs HC ,0.0001 16.278(4.892–54.170) 0.00027 10.712(2.983–38.464) 40.7 ,0.0001 0.01 6.708(2.961–15.19)
MA Vs HC ,0.0001 13.065(3.782–45.130) 0.012 9.452(1.626–54.938) 24.12 ,0.0001 0.01 8.135(3.192–20.74)
Association of T allele with migraine susceptibility
Migraine Vs HC ,0.0001 2.618(1.943–3.529) ,0.0001 2.248(1.603–3.152) 69.78 ,0.0001 0.01 2.487(1.991–3.106)
MO Vs HC ,0.0001 2.942(2.107–4.109) ,0.0001 2.314(1.610–3.327) 68.38 ,0.0001 0.01 2.662(2.085–3.398)
MA Vs HC 0.0002 2.116(1.425–3.141) 0.018 2.030(1.131–3.645) 25.08 ,0.0001 0.01 2.166(1.568–2.993)
Females
Migraine Vs HC ,0.0001 2.810(1.950–4.047) ,0.0001 2.479(1.655–3.713) 57.56 ,0.0001 0.01 2.659(2.03–3.483)
MO Vs HC ,0.0001 2.977(1.969–4.500) ,0.0001 2.533(1.643–3.905) 51.7 ,0.0001 0.01 2.749(2.041–3.702)
MA Vs HC ,0.0001 2.584(1.622–4.115) 0.016 2.303(1.168–4.541) 27.6 ,0.0001 0.01 2.505(1.712–3.666)
Association using dominant (CT+TT) model
Migraine Vs HC ,0.0001 3.557(2.326–5.439) ,0.0001 3.147(1.934–5.121) 63.26 ,0.0001 0.01 3.419(2.49–4.693)
MO Vs HC ,0.0001 4.713(2.807–7.914) ,0.0001 3.442(2.007–5.903) 62.12 ,0.0001 0.01 4.046(2.799–5.849)
MA Vs HC 0.003 2.363(1.349–4.136) 0.045 2.394(1.021–5.616) 17.82 0.0013 0.01 2.486(1.568–3.94)
Females
Migraine Vs HC ,0.0001 3.372(2.023–5.621) ,0.0001 3.625(2.012–6.534) 47.2 ,0.0001 0.01 3.436(2.345–5.034)
MO Vs HC ,0.0001 4.173(2.241–7.769) ,0.0001 3.868(2.018–7.412) 43.8 ,0.0001 0.01 3.931(2.522–6.128)
MA Vs HC 0.005 2.569(1.322–4.989) 0.037 2.967(1.069–8.236) 17.2 0.0018 0.01 2.672(1.544–4.623)
MA migraine with aura, MO migraine without aura, HC healthy controls, OR odds ratio, CI confidence interval, ORMH Mantel – Heanszel odds ratio.
ap Values in bold denotes significance.
doi:10.1371/journal.pone.0034828.t001
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functionally relevant CYP19A1 and ESR2 gene polymorphisms in
our study.
CYP19A1 is located in short arm of chromosome 15 (15q21). It
is a member of cytochrome P450 family and codes for aromatase
enzyme which catalyzes the final step of estrogen biosynthesis. Our
data indicates strong association of CYP19A1 39UTR polymor-
phisms with migraine susceptibility. The variant genotype and
allele of rs10046 polymorphism impart a potentially significant
migraine risk especially in females. The carrier analysis further
implies the effect of variant allele in dominant form as well.
Dunning et al. [17] for the first time reported the association of C
allele with low estrone and estradiol levels. The result was
replicated by Haiman et al. [3] This marker has been associated
with altered pituitary suppression in premenopausal women [18].
It also showed significant risk with breast cancer [19] and essential
hypertension [20]. On the contrary, rs4646 variant (T) polymor-
phism was found to have a protective effect in susceptibility to
migraine. Haiman et al. [3] reported significantly increased estrone
and estradiol levels in individuals with GG genotype. This
polymorphism has a significant role in determining efficacy of
antiaromatase therapy [21]. The 39UTR polymorphisms are
located 142 bp apart. As expected, these polymorphisms are in
linkage disequilibrium. Haplotype analysis of CYP19A1 polymor-
phisms revealed the significant predominance of two haplotype
groups in migraine patients. Both these haplotype groups consisted
of the variant of rs10046 polymorphism, reconfirming its role in
migraine susceptibility.
Estrogen hormone carries out its physiological functions
through its receptors. ESRa is expressed by many of the trigeminal
neurons. The gene encoding estrogen receptor alpha, (ESR1)
localized in 6q25.1 locus is the most widely studied hormonal
pathway gene in migraine. We analyzed two intronic (intron 1)
and two exonic (exons 4 & 8) polymorphisms of this gene.
However, we could establish a significant relationship of a single
intronic polymorphism (rs2234693) in migraine with aura patients.
The existing literature reveals conflicting reports [8,13]. The
nearby SNP rs9340799 was not associated with migraine. The lack
of association of the exonic polymorphisms is previously
documented by several authors [8,9]. These polymorphisms do
not result in any change in amino acid sequence. This further
strengthens our findings.
On the contrary, a recent meta analysis of ESR1 polymorphisms
reported significant associations of exonic polymorphisms [22].
However, among six studies [5,8,9,10,11,13] on ESR1 rs1801132
polymorphism, only two studies [5,11] reported significant
associations with migraine. Similarly, only a single study [12]
among four reports on ESR1 rs2228480 polymorphism showed
significant findings [9,10,11,12]. Thus, our results are in
accordance with majority of the published results. The discor-
dance with the results of meta analysis could be explained by the
large variations in sample size of the included studies, which could
tilt the final outcome on the studies with larger samples.
The intronic polymorphisms are at a distance of 50 bp and
hence are in strong linkage disequilibrium. The polymorphisms
were not in LD with other polymorphisms. Similarly, Colson et al.
[8] did not find LD between exon 8 marker with intronic and exon
4 markers. However, the authors reported LD between intron1
and exon 4 markers. But the distance (,102 kb) between the
markers could explain our findings.
We were able to identify a particular haplotype group showing
protective effect of migraine. This particular group consists of
variant allele (G) of one intronic polymorphism (rs9340799)
whereas the wild alleles of other polymorphisms. Hence, it shows
the antagonistic role of the two intronic polymorphisms. Literature
review also reveals that XbaI*G (variant) and PvuII*C (wild) SNPs
are associated with elevated serum estradiol (E2) production [6,7].
Hence, these alleles may impart a protective effect. The results of
our study could be justified by the role of amino terminal portion
in transcriptional activation and its association with various
Table 2. Association study of CYP19A1 rs4646 polymorphism.
Primary cohort Replicative cohort Meta analysis
Fisher’s
method
Benjamini-
Hochberg
FDR test Mantel-Haenszel test
p
a OR(95%CI) p
a OR(95%CI) X
2 p
a pcorr
a ORMH(95%CI)
Association of GT genotype with migraine susceptibility
Females
Migraine Vs HC 0.022 0.544(0.324–0.915) 0.002 0.388(0.212–0.711) 20.06 0.0005 0.01 0.5465(0.3781–0.7899)
MA Vs HC 0.015 0.427(0.215–0.846) 0.029 0.296(0.099–0.880) 15.48 0.0038 0.01 0.4856(0.2789–0.8456)
Association of T allele with migraine susceptibility
MA Vs HC 0.034 0.639(0.422–0.966) 0.014 0.417(0.208–0.835) 15.3 0.0041 0.01 0.5695(0.4007–0.8093)
Females
Migraine Vs HC 0.011 0.629(0.441–0.897) 0.029 0.641(0.430–0.956) 16.1 0.0029 0.01 0.6353(0.4871–0.8287)
MA Vs HC 0.002 0.452(0.274–0.747) 0.027 0.416(0.191–0.906) 19.64 0.0006 0.01 0.442(0.29–0.6737)
Association using dominant (GT+TT) model
Females
Migraine Vs HC 0.010 0.529(0.326–0.857) 0.004 0.455(0.265–0.780) 20.26 0.0004 0.01 0.4953(0.3457–0.7096)
MA Vs HC 0.003 0.380(0.201–0.721) 0.016 0.303(0.114–0.801) 19.9 0.0005 0.01 0.3531(0.2072–0.6017)
MA migraine with aura, HC healthy controls, OR odds ratio, CI confidence interval, ORMH Mantel – Heanszel odds ratio.
ap Values in bold denotes significance.
doi:10.1371/journal.pone.0034828.t002
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effect of ESR1 polymorphisms on migraine risk diminish from
amino to carboxy terminal.
ESRb is mostly expressed by inhibitory neurons in cerebral
cortex. Therefore, it regulates cortical excitability and spreading
depression [24] involved in migraine pathophysiology. It is
encoded by ESR2 gene located in 14q22-24. A promoter
polymorphism (rs1271572) has a functional effect on transcrip-
tional factor binding and gene expression [14]. The other selected
polymorphism (rs1256049) is present in exon 5 which results in a
silent change in amino acid. However, we were unable to find an
association of these polymorphisms in migraine. No previous
reports are available for these polymorphisms in migraine.
We also studied the genetic interactions. Our study supports the
significant interactions between CYP19A1 and ESR polymor-
phisms. Thus we infer that though individual polymorphisms have
no role but in the presence of other genetic variants, these could be
a possible risk factor (as in case of ESR1 intronic polymorphisms).
We obtained antagonistic interaction of ESR1 rs9340799 with the
CYP19A1 39UTR polymorphisms. This SNP showed an increased
risk with rs10046 polymorphism whereas a protective effect with
rs4646 polymorphism. It implies the role of CYP19A1 polymor-
phisms in defining the effect on migraine susceptibility. Similarly,
we also analyzed gene – gene interaction of haplotypes. In this case
also antagonistic role of ESR1 H haplotype was observed with
CYP19A1 haplotypes. These findings further strengthen the effect
of CYP19A1 polymorphisms on migraine susceptibility. This is
further supported by the fact that haplotype H consists of both the
variants of intronic polymorphisms shown to have opposite effect
on migraine susceptibility. So the individual effect of the haplotype
is more or less nullified. In other words, the same haplotype of
ESR1 may show protective effect or risk depending on the
CYP19A1 haplotypes. Hence, we conclude that CYP19A1 poly-
morphisms and haplotypes are the major causal factors for
migraine susceptibility. However, their effect is enhanced on
genetic interaction with ESR1 polymorphisms and haplotypes. No
other group has analyzed or reported such genetic interactions.
The variants of associated polymorphisms (rs10046, rs4646 and
rs2234693) are found to affect estrogen levels (either high or low).
So, the bimodal effect of estrogen is implicated in migraine
pathophysiology. Estrogen withdrawal is the most well accepted
theory especially in migraine without aura. It is attributed to the
fact that frequency of attacks increase with menstruation and use
of oral contraceptives. In addition, migraine attacks subside during
Table 4. Association study of ESR1 polymorphisms.
Primary cohort Replicative cohort Meta analysis
Fisher’s method
Benjamini-
Hochberg
FDR test
Mantel-Haenszel
test
p
a OR(95%CI) p
a OR(95%CI) X
2 p
a pcorr
a ORMH(95%CI)
ESR1 rs2234693
Association of TT genotype with migraine susceptibility
Migraine Vs HC 0.007 2.477(1.275–4.813) 0.081 1.847(0.927–3.681) - - - -
MO Vs HC 0.006 2.822(1.350–5.898) 0.498 1.302(0.607–2.792) - - - -
MA Vs HC 0.177 1.911(0.747–4.891) 0.002 6.205(1.945–19.792) - - - -
Association of T allele with migraine susceptibility
Migraine Vs HC 0.002 1.547(1.167–2.050) 0.237 1.217(0.879–1.684) - - - -
MO Vs HC 0.003 1.612(1.172–2.219) 0.112 0.737(0.506–1.074) - - - -
MA Vs HC 0.060 1.438(0.985–2.100) 0.004 2.305(1.305–4.070) 16.66 0.0023 0.01 1.634(1.196–2.233)
ESR1 rs1801132
Association of GG genotype with migraine susceptibility
Migraine Vs HC 0.138 1.705(0.843–3.450) 0.431 0.701(0.289–1.698) - - - -
MO Vs HC 0.128 1.842(0.839–4.046) 0.486 0.710(0.271–1.860) - - - -
MA Vs HC 0.399 1.491(0.590–3.767) 0.595 0.652(0.135–3.152) - - - -
ESR1 rs2228480
Association of AA genotype with migraine susceptibility
Migraine Vs HC 0.420 0.657(0.238–1.820) 0.811 0.870(0.279–2.719) - - - -
MO Vs HC 0.415 0.603(0.179–2.030) 0.829 0.874(0.256–2.980) - - - -
MA Vs HC 0.662 0.740(0.191–2.860) 0.933 0.911(0.106–7.860) - - - -
ESR1 rs 9340799
Association of GG genotype with migraine susceptibility
Migraine Vs HC 0.883 1.047(0.566–1.940) 0.878 1.055(0.531–2.094) - - - -
MO Vs HC 0.513 1.254(0.636–2.475) 0.288 0.647(0.290–1.444) - - - -
MA Vs HC 0.455 0.708(0.286–1.751) 0.016 4.000(1.296–12.342) - - - -
MA migraine with aura, MO migraine without aura, HC healthy controls, OR odds ratio, CI confidence interval, ORMH Mantel – Heanszel odds ratio.
ap Values in bold denotes significance.
doi:10.1371/journal.pone.0034828.t004
Role of Aromatase Polymorphisms in Migraine
PLoS ONE | www.plosone.org 6 April 2012 | Volume 7 | Issue 4 | e34828pregnancy and with menopause - two phases of high estrogen
levels in women. On the other hand, high estrogen levels influence
gene expression and signaling, finally leading to inflammatory pain
[25]. Estrogen enhances cortical spreading depression involved in
the pathophysiology of migraine with aura [26]. Hence abrupt
estrogen decline as well as abnormally high estrogen levels leads to
trigeminal pain [27].
Our study reports various significant findings. First of all, we are
the first group to report significant associations of CYP19A1 39
UTR polymorphisms. Secondly, we identified protective haplo-
type groups in ESR1 gene. Thirdly, we defined significant genetic
interactions between CYP19A1-ESR1 gene polymorphisms.
Fourthly, we were also able to show significant genetic interaction
of haplotypes. Finally, we were able to replicate all the significant
findings. Thus our results do not lack validation as is the case of
other association studies. In addition, the data of both the cohorts
were pooled using statistical tests (Fisher’s method and Mantel-
Haenszel test). So, in contrast to direct pooling, there is no need of
additional adjustments or corrections. We are the first group to use
such tests for validating data in defining role of hormone related
genes in migraine.
In the era of genome wide association studies (GWAS), our
candidate gene case-control study suffers from limitations
especially in terms of sample size although our study achieved
80% power. Furthermore, limited sample size in some subgroups
is another important issue. However, we have tried to overcome it
by applying Benjamini – Hochberg FDR test for multiple
comparisons. Secondly, wide confidence interval in case of
rs10046 polymorphism (wild Vs variant genotype) is also of
concern. In such cases, pooling by meta analysis has resulted in
narrowing the confidence interval to some extent. Lastly, even
though association studies are considered to be somewhat
outdated in the GWAS era, our study provides some definite
insights for future work.
In conclusion, we report the significant association of CYP19A1
39UTR and ESR1 rs2234693 polymorphism with migraine risk.
Table 5. Gene-Gene Interaction of genotypes.
Genotype
interactions
a Primary cohort Replicative cohort Meta analysis
Fisher’s
method
Benjamini-
Hochberg
FDR test Mantel-Haenszel test
p
b OR(95%CI) p
b OR(95%CI) X
2 p
b pcorr
b ORMH(95%CI)
CYP19A1 rs10046- ESR2 rs1271572
1-1 0.034 1.676(1.038–2.706) 0.015 1.938(1.138–3.301) 15.16 0.0044 0.01 1.637(1.155–2.32)
2-1 0.021 4.584(1.264–16.620) 0.019 5.068(1.299–19.778) 15.65 0.0035 0.01 4.202(1.657–10.66)
CYP19A1rs10046-ESR1 rs2234693
2-1 ,0.0001 12.535(3.666–42.856) 0.027 4.646(1.190–18.134) 26.84 ,0.0001 0.01 8.138(3.385–19.56)
1-2 0.025 2.662(1.130–6.269) 0.012 3.058(1.280–7.307) 16.22 0.0027 0.01 2.053(1.131–3.727)
CYP19A1rs10046- ESR1 rs9340799
2-1 0.001 12.970(2.960–56.836) 0.014 7.238(1.490–35.162) 22.36 0.0002 0.01 7.91(2.715–23.04)
1-2 0.054 2.400(0.985–5.848) 0.014 3.187(1.269–8.003) 14.38 0.0062 0.01 2.081(1.11–3.901)
CYP19A1 rs4646-ESR1 rs9340799
1-1 0.017 0.513(0.297–0.887) 0.006 0.387(0.198–0.757) 18.38 0.001 0.01 0.3457(0.2221–0.5382)
OR odds ratio, CI confidence interval, ORMH Mantel – Heanszel odds ratio.
a1&2 represent heterozygous and variant genotypes, respectively.
bp Values in bold denotes significance.
doi:10.1371/journal.pone.0034828.t005
Table 6. Gene-Gene Interaction of haplotypes.
Haplotype
interactions Primary cohort Replicative cohort Meta analysis
Fisher’s
method
Benjamini-
Hochberg
FDR test Mantel-Haenszel test
p
a OR(95%CI) p
a OR(95%CI) X
2 p
a pcorr
a ORMH(95%CI)
CYP19A1 – ESR1
01-H 0.025 0.272(0.087–0.851) 0.021 0.089(0.012–0.691) 15.10 0.0045 0.01 0.153(0.058–0.406)
10-H 0.032 2.894(1.093–7.663) 0.091 2.453(0.866–6.948) 11.68 0.0199 0.02 2.555(1.271–5.138)
OR odds ratio, CI confidence interval, ORMH Mantel – Heanszel odds ratio.
ap Values in bold denotes significance.
doi:10.1371/journal.pone.0034828.t006
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PLoS ONE | www.plosone.org 7 April 2012 | Volume 7 | Issue 4 | e34828We also found increased risk with certain CYP19A1 and ESR1
haplotype groups. Similarly, significant gene interactions of
genotypes and haplotypes were also identified. Based on these
findings, we suggest CYP19A1 polymorphisms to be the major
contributing factor in migraine susceptibility rather than ESR1and
ESR2 polymorphisms as shown by interactions of genotypes and
haplotypes. In future, more studies in other ethnic groups should
focus on CYP19A1 polymorphisms to better understand the
pathobiology of migraine.
Materials and Methods
Ethics statement
The study protocol was approved by the Institutional ethical
committee of SGPGIMS Lucknow (India). Written informed
consent was taken by all the participants.
Subjects
Normotensive migraine patients were recruited from the
Neurology Out Patient Clinic (OPD) of Sanjay Gandhi Postgrad-
uate Institute of Medical Sciences (SGPGIMS), Lucknow, India.
Diagnosis of migraine was carried out according to the criteria of
the International Headache Society (IHS) [28]. The patients were
recruited in two cohorts - primary and replicative. The patients
(n=207) recruited in the period 2006–2008 were included in
primary cohort and those recruited from 2009 onwards (n=127)
were included in replicative cohort. Simultaneously, 200 healthy
controls (HC) from volunteers like healthy staff members and
general population were included in the study. The healthy
controls were mean age, sex, ethnicity matched and free from any
organic disease. The controls were especially checked for the
presence of migraine and other headache disorders. Persons free
from such headaches were enrolled for the study. The recruitment
of the subjects was based on the inclusion and exclusion criteria
[28]. In general, subjects with age of onset ,50 years and attack
frequency of at least 1 per month for previous 3 months were
included. Migraine patients with comorbid disorders – vascular
diseases (eg. hypertension, ischemic heart disease); neurological
disorders (eg. epilepsy, stroke); hormonal disorders (eg. hypothy-
roidism) and non migrainous headaches (eg. tension headaches)
were excluded. Secondary causes of migraine like post head injury
migraineurs were also excluded from the study. The family history
and general questionnaire of all the subjects recruited for the study
were taken to ensure their ethnicity. After informed consent, 3 ml
of blood was collected in EDTA vial and stored at 270uC.
Methods
DNA isolation. Genomic DNA was extracted from frozen
blood using the standard salting out method [29].
Genotyping of CYP19A1 polymorphisms. Genotyping of
rs10046 and rs4646 polymorphisms were done by Hexaprimer
Amplification Refractory Mutation System – polymerase chain
reaction (PCR) as previously described [30].
Genotyping of ESR1 polymorphisms. Genotyping was
done by PCR- restriction fragment length polymorphism
(RFLP). The promoter polymorphisms were genotyped as
previously described [31]. ESR1 G594A was genotyped using
BtgI [12] and C325G polymorphism was genotyped using HinfIa s
described by Iwase et al. [32].
Genotyping of ESR2 polymorphisms. rs 1271572
polymorphism was amplified using self designed primers: 59
CTGCCCACCCCTCTTCTC39 and 59 CCATCTTTGGAG
CCTGTCTT39 and genotyped by BsaI whereas rs1256049 was
genotyped using RsaI as previously described [33].
Quality control. 20% of samples were re-genotyped by
another laboratory member to improve the quality of genotyping
and its validity, and no discrepancy in genotyping was found.
Genotyping of 5% of these samples was reconfirmed through
sequencing.
Statistical analysis. Sample size was calculated using
Quanto version 1.1.1.The study achieved 80% power. Goodness
of fit x
2 test was used to check Hardy Weinberg Equilibrium in
control population. Logistic regression analyses were done using
SPSS version 15. The results were analyzed separately at
genotypic and the allelic levels. Furthermore, linkage
disequilibrium and haplotype analysis was done using SNP
Analyzer version 1.2. In addition, the results were also analyzed
using dominant model and trend per copy of haplotypes. Finally,
gene-gene interactions were also analyzed.
The results of primary cohort were validated in the replicative
cohort. On obtaining significant associations in both the cohorts,
the results were pooled by meta analysis using Fisher’s method (X
2
and p value) and Mantel-Haenszel test using Open Epi version
2.3.1 for odds ratio (OR) calculation. Benjamini – Hochberg false
discovery rate (FDR) test was used to correct for multiple
comparisons yielding pcorr.p corr value less than 0.05 was
considered as significant.
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